Thursday, February 14, 2013
Publication and contact
Patient induced pluripotent
stem (iPS) cell-derived cardiomyocytes as models for right ventricular
from patient-derived iPS cells could help identify new treatments for right
ventricular dysplasia/cardiomyopathy. Fibroblasts were isolated from an adult
patient, reprogrammed into iPS cells and subsequently differentiated into
cardiomyocytes. In culture, the resulting cells recapitulated an adult
cardiomyocyte phenotype, showing exaggerated lipogenesis and deficiencies in
calcium handling and greater apoptosis than control cells. Next steps include
extending the findings to additional subtypes of right ventricular
dysplasia/cardiomyopathy and using the patient-derived cells to evaluate
Published online Feb. 14, 2013
Patents pending; licensing
Kim, C. et al. Nature;
published online Jan. 27, 2013;
Contact: Huei-Sheng Vincent Chen, Sanford-Burnham Medical
Research Institute, La Jolla, Calif.
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]